Insight Molecular Diagnostics (IMDX) has appointed Dr. Nick Ioannou to the position of Vice President, Medical Affairs. Ioannou is a physician-scientist with more than three decades of highly relevant experience spanning clinical practice, diagnostics, regulatory affairs, medical education, and medical affairs. His background includes over fifteen years of field-based collaboration with key opinion leaders across multiple therapeutic areas, particularly in organ transplantation, nephrology, cardiology, pulmonology, genetics, and oncology. He previously served Guardant Health as a senior staff medical science liaison and field director.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMDX:
- Regulatory Momentum and Expanding Clinical Footprint Position Insight Molecular Diagnostics for a Pivotal 2026 Ramp
- iMDx prepares for U.S. commercial launch of GraftAssureDx
- Fourteen new option listings on November 12th
- OncoCyte Corp’s Earnings Call: Progress Amid Challenges
- Insight Molecular Diagnostics: Promising Growth with GraftAssureIQ and Strategic Expansion Plans Reinforce Buy Rating
